deaths (OS)

metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)

versus everolimus
nivolumab alone vs. everolimus 1 -768 [-1449; -86] /10000
183/410 vs. 215/411